BlossomHill Therapeutics Inc.
Organization details
- Legal name
- BlossomHill Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- BLSM
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001839970
- EIN
- 85-1578711
Board of directors
- Since 2026
- Since 2026
-
Jingrong Jean Cui · Director · President and CEOSince 2026
- Since 2026
-
Sheila Gujrathi · DirectorSince 2026
-
Sundeep Agrawal · DirectorSince 2026
-
Yishan Li · Director · Executive ChairmanSince 2026
Chief executives
Board connections
5 of this board's directors also sit on 20 other boards. 19 are in the same sector.
-
BridgeBio Oncology Therapeutics Inc. Same sectorvia Bihua Chen and John P. Schmid
- via Bihua Chen and John P. Schmid
-
ADARx Pharmaceuticals Inc. Same sectorvia Carl L. Gordon
-
Adicet Bio Inc. Same sectorvia Carl L. Gordon
-
AnaptysBio Inc. Same sectorvia John P. Schmid
-
ArriVent BioPharma Inc. Same sectorvia Carl L. Gordon
-
Biomea Fusion Inc. Same sectorvia Bihua Chen
-
Bolt Biotherapeutics Inc. Same sectorvia Sheila Gujrathi
-
Compass Therapeutics Inc. Same sectorvia Carl L. Gordon
-
Design Therapeutics Inc. Same sectorvia John P. Schmid
-
Electra Therapeutics Inc. Same sectorvia Carl L. Gordon
-
Erasca Inc. Same sectorvia Bihua Chen
-
First Tracks Biotherapeutics Inc. Same sectorvia John P. Schmid
-
Janux Therapeutics Inc. Same sectorvia Sheila Gujrathi
-
Keros Therapeutics Inc. Same sectorvia Carl L. Gordon
-
MBX Biosciences Inc. Same sectorvia Carl L. Gordon
-
PAVmed Inc. Same sectorvia Sundeep Agrawal
-
Processa Pharmaceuticals Inc. Same sectorvia Sheila Gujrathi
-
Scribe Therapeutics Inc. Same sectorvia Carl L. Gordon
-
Xeris Biopharma Holdings Inc. Same sectorvia John P. Schmid
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $25,181,900
- 7 purchases by 6 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 10, 2026 | Sundeep Agrawal Director | Derivative conversion | +578,524 | — | — |
| Aug 10, 2026 | Bihua Chen Director, 10% owner | Derivative conversion | +1,599,993 | — | — |
| Aug 10, 2026 | John P. Schmid Director | Open-market purchase | +6,000 | $16.00 | $96,000 |
| Aug 10, 2026 | Jason A. Keyes Officer (Chief Financial Officer) | Open-market purchase | +700 | $16.00 | $11,200 |
| Aug 10, 2026 | Yishan Li Director, Officer (Executive Chairman), 10% owner | Derivative conversion | +1,600,682 | — | — |
| Aug 10, 2026 | Jingrong Jean Cui Director, Officer (President and CEO), 10% owner | Derivative conversion | +1,600,682 | — | — |
| Aug 10, 2026 | OrbiMed Capital GP VIII LLC Director | Derivative conversion | +1,039,996 | — | — |
| Aug 10, 2026 | Carl L. Gordon Director | Derivative conversion | +1,039,996 | — | — |
| Aug 10, 2026 | Bihua Chen Director, 10% owner | Derivative conversion | +1,701,541 | — | — |
| Aug 10, 2026 | Yishan Li Director, Officer (Executive Chairman), 10% owner | Derivative conversion | +113,435 | — | — |
| Aug 10, 2026 | Jingrong Jean Cui Director, Officer (President and CEO), 10% owner | Derivative conversion | +113,435 | — | — |
| Aug 10, 2026 | Liptak Vincent Paul Officer (General Counsel) | Open-market purchase | +2,200 | $16.00 | $35,200 |
| Aug 10, 2026 | OrbiMed Capital GP VIII LLC Director | Derivative conversion | +1,049,283 | — | — |
| Aug 10, 2026 | Carl L. Gordon Director | Derivative conversion | +1,049,283 | — | — |
| Aug 10, 2026 | Bihua Chen Director, 10% owner | Open-market purchase | +312,500 | $16.00 | $5,000,000 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about BlossomHill Therapeutics Inc.
Who is the CEO of BlossomHill Therapeutics Inc.?
Jingrong Jean Cui has been BlossomHill Therapeutics Inc.'s President and CEO since August 2026.
How many directors are on BlossomHill Therapeutics Inc.'s board?
BlossomHill Therapeutics Inc.'s board has 7 directors: Bihua Chen, Carl L. Gordon, Jingrong Jean Cui, John P. Schmid, Sheila Gujrathi, Sundeep Agrawal and Yishan Li.
Are BlossomHill Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, BlossomHill Therapeutics Inc. insiders bought $25.2 million of shares in 7 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="blossomhill-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.